AI-Guided CAR-T Cell Therapy Trial
Advanced AI-guided CAR-T cell therapy trial for relapsed B-cell lymphomas. Breakthrough treatment using artificial intelligence optimization.
Phase II Trial of AI-Guided CAR-T Cell Therapy for Relapsed/Refractory B-Cell Lymphomas
Full Title
A phase II, single-arm, multicenter study to evaluate the safety and efficacy of artificially intelligent-optimized CD19-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphomas
Purpose
This study uses artificial intelligence to design better CAR-T cell therapy. We take your immune cells, engineer them using AI-guided improvements to fight lymphoma more effectively, then give them back to you. The AI helps optimize how the cells are modified to improve their cancer-fighting ability while reducing side effects.
Primary Objectives
- Evaluate the overall response rate of AI-optimized CAR-T cells
- Assess the safety profile and incidence of cytokine release syndrome
- Determine the persistence and expansion of AI-modified CAR-T cells
Diseases
- Leukemia/Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
Who Can Join this Trial
To participate in this study, you must meet ALL of the following criteria
- Have histologically confirmed CD19-positive B-cell non-Hodgkin lymphoma
- Have relapsed after or are refractory to at least two prior lines of systemic therapy
- Have chemotherapy-refractory disease
- ECOG performance status 0-1
- Age 18-75 years
- Adequate organ function including heart, liver, and kidney function
- Left ventricular ejection fraction ≥45%
- Adequate pulmonary function with oxygen saturation ≥92% on room air
- No active CNS involvement by lymphoma
- No prior CAR-T cell therapy or gene therapy
Access Clinical Trials
Locations
CONTACT
📞 Call Now: 1-800-NEOVITA (1-800-636-8482)
🌐 Online Scheduling: Schedule Your Consultation
📧 Email: info@neovitaoncology.com